Clinical Trial

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-24; most recent amendment 2026-06-22.
Status change: Active, Not Recruiting → Recruiting 2026-02-25
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-12-10
Trial Details
NCT Number NCT07193550
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Exelixis
Conditions Bone Sarcomas
Enrollment 70 participants
Start Date 2025-12-05
Primary Completion 2029-10-31 (estimated)
Study Completion 2031-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24